BC
Boxer Capital Portfolio holdings
AUM
$2.04B
This Quarter Return
+17%
1 Year Return
+108.35%
3 Year Return
+260.95%
5 Year Return
+1,103.68%
10 Year Return
–
AUM
$2.04B
AUM Growth
+$2.04B
(+7.3%)
Cap. Flow
+$64.9M
Cap. Flow
% of AUM
3.19%
Top 10 Holdings %
Top 10 Hldgs %
54.88%
Holding
72
New
11
Increased
1
Reduced
5
Closed
4
Top Buys
| 1 |
Instil Bio
TIL
|
$23.9M |
| 2 |
Kymera Therapeutics
KYMR
|
$21.3M |
| 3 |
Nurix Therapeutics
NRIX
|
$12.7M |
| 4 |
uniQure
QURE
|
$11M |
| 5 |
Apogee Therapeutics
APGE
|
$10.5M |
Top Sells
| 1 |
Fate Therapeutics
FATE
|
$11.4M |
| 2 |
Allogene Therapeutics
ALLO
|
$8.97M |
| 3 |
Nkarta
NKTX
|
$7.13M |
| 4 |
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
|
$7.08M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
$2.85M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Kymera Therapeutics
KYMR
$2.95B
| $21.3M | 1.05% |
+450,000
| New | +$21.3M |
|
27
Spyre Therapeutics
SYRE
$996M
| $20.5M | 1.01% |
696,480
| – | – |
|
28
Kura Oncology
KURA
$686M
| $19.5M | 0.96% |
1,000,000
| – | – |
|
29
KalVista Pharmaceuticals
KALV
$678M
| $18.4M | 0.9% |
1,590,000
| – | – |
|
|
30
Nkarta
NKTX
$151M
| $18.2M | 0.89% |
4,029,606
-1,577,744
| -28% | -$7.13M |
|
31
Oric Pharmaceuticals
ORIC
$994M
| $17.8M | 0.87% |
1,732,571
| – | – |
|
32
Structure Therapeutics
GPCR
$1.11B
| $17.6M | 0.86% |
400,000
| – | – |
|
|
33
Fate Therapeutics
FATE
$120M
| $17.4M | 0.85% |
4,960,910
-3,255,000
| -40% | -$11.4M |
|
34
Enliven Therapeutics
ELVN
$1.2B
| $17.1M | 0.84% |
671,358
| – | – |
|
35
Replimune Group
REPL
$422M
| $16.8M | 0.83% |
1,536,341
| – | – |
|
36
Day One Biopharmaceuticals
DAWN
$769M
| $16.6M | 0.81% |
1,189,943
| – | – |
|
37
Cullinan Oncology
CGEM
$445M
| $15.2M | 0.75% |
907,895
+250,000
| +38% | +$4.19M |
|
38
Arvinas
ARVN
$568M
| $15M | 0.74% |
608,614
| – | – |
|
|
CLYM
39
Climb Bio, Inc. Common Stock
CLYM
$151M
| $13.3M | 0.65% |
2,603,190
| – | – |
|
40
Relay Therapeutics
RLAY
$619M
| $12.9M | 0.63% |
1,819,132
| – | – |
|
|
41
Nurix Therapeutics
NRIX
$714M
| $12.7M | 0.62% |
+563,067
| New | +$12.7M |
|
42
Prothena Corp
PRTA
$441M
| $11.5M | 0.57% |
690,000
| – | – |
|
|
43
uniQure
QURE
$896M
| $11M | 0.54% |
+2,225,000
| New | +$11M |
|
|
44
Apogee Therapeutics
APGE
$2.17B
| $10.5M | 0.52% |
+179,000
| New | +$10.5M |
|
45
Olema Pharmaceuticals
OLMA
$375M
| $7.76M | 0.38% |
650,000
| – | – |
|
46
Iovance Biotherapeutics
IOVA
$807M
| $7.04M | 0.35% |
750,000
| – | – |
|
47
Century Therapeutics
IPSC
$42.5M
| $6.67M | 0.33% |
3,900,000
-1,001,603
| -20% | -$1.71M |
|
48
Jasper Therapeutics
JSPR
$45.5M
| $6.58M | 0.32% |
350,000
| – | – |
|
49
Sana Biotechnology
SANA
$777M
| $6.43M | 0.32% |
1,545,000
| – | – |
|
50
Terns Pharmaceuticals
TERN
$609M
| $6.27M | 0.31% |
+752,000
| New | +$6.27M |
|